My takeaway is since 1-5 children with cancer die, and many do not have Delta 32 deletion and could benefit from CCR5 100% Receptor Occupancy, Leronlimab could be a genetic intervention that gives these young bodies a chance to do it on their own in adolescence and beyond.

Nice thought anyways. GLTU.